License & Royalty was Regenxbio’s largest product and service line in fiscal 2025, bringing in $156.27M of $170.44M (92%).
| Product and Service | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| License & Royalty | $112.72M | $90.24M | $81.96M | $156.27M | ||||||
| Service | — | — | $1.37M | $14.17M | ||||||
| License | — | — | — | — | ||||||
| Other | — | — | — | — | ||||||
| Total | $112.72M | $90.24M | $83.33M | $170.44M |
Regenxbio brought in $170.44M from its two product and service lines in fiscal 2025, the year ended December 31, 2025. That was up 104.5% from $83.33M in fiscal 2024. License & Royalty was the largest at $156.27M (91.7%), ahead of Service at $14.17M (8.3%).
Compared with fiscal 2024, Service grew 936.1% to $14.17M and License & Royalty grew 90.7% to $156.27M.
Regenxbio began breaking out Service in fiscal 2024, when it brought in $1.37M.
Regenxbio (RGNX) reports its revenue by product and service. In fiscal 2025, License & Royalty was its largest product and service line, bringing in $156.27M (91.7% of the total), followed by Service at $14.17M (8.3%).
License & Royalty was Regenxbio's largest product and service line in fiscal 2025, bringing in $156.27M, or 91.7% of the $170.44M total across its two product and service lines.
Service grew faster than License & Royalty in fiscal 2025, up 936.1% from $1.37M to $14.17M. License & Royalty grew 90.7% to $156.27M.
Every figure comes from Regenxbio's annual financial filings, as reported. Each line keeps the name Regenxbio gives it, and years follow its fiscal calendar.
Regenxbio's revenue by product and service goes back to fiscal 2016, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.